TWI867026B - 前體脂質體十一酸睪固酮調配物 - Google Patents

前體脂質體十一酸睪固酮調配物 Download PDF

Info

Publication number: TWI867026B
Authority: TW; Taiwan
Prior art keywords: tsx; dose; testosterone; plasma; powder dispersion
Prior art date: 2019-08-09

Application number

TW109127792A

Other languages

English (en)

Chinese (zh)

Other versions

TW202216162A (zh

Inventor

維然Ｇ卡達吉

納塔拉傑文卡特森

尼汀Ｋ史華那卡

特蕾莎洪

拉瑪錢德朗席魯柯特

古魯貝塔傑利

Original Assignee

美商泰索爾克斯製藥有限責任公司

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2019-08-09

Filing date

2020-08-14

Publication date

2024-12-21

2020-08-14 Application filed by 美商泰索爾克斯製藥有限責任公司 filed Critical 美商泰索爾克斯製藥有限責任公司

2022-05-01 Publication of TW202216162A publication Critical patent/TW202216162A/zh

2024-12-21 Application granted granted Critical

2024-12-21 Publication of TWI867026B publication Critical patent/TWI867026B/zh

Links

UDSFVOAUHKGBEK-CNQKSJKFSA-N testosterone undecanoate Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H](OC(=O)CCCCCCCCCC)[C@@]1(C)CC2 UDSFVOAUHKGBEK-CNQKSJKFSA-N 0.000 title claims abstract description 283
229960000746 testosterone undecanoate Drugs 0.000 title claims abstract description 207
239000000203 mixture Substances 0.000 title description 55
238000009472 formulation Methods 0.000 title description 46
239000006185 dispersion Substances 0.000 claims abstract description 70
239000000843 powder Substances 0.000 claims abstract description 68
MUMGGOZAMZWBJJ-DYKIIFRCSA-N Testostosterone Chemical compound O=C1CC[C@]2(C)[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 MUMGGOZAMZWBJJ-DYKIIFRCSA-N 0.000 claims description 74
239000002775 capsule Substances 0.000 claims description 48
239000006186 oral dosage form Substances 0.000 claims description 37
229960003604 testosterone Drugs 0.000 claims description 37
239000002502 liposome Substances 0.000 claims description 32
239000002243 precursor Substances 0.000 claims description 27
229930195725 Mannitol Natural products 0.000 claims description 19
239000000594 mannitol Substances 0.000 claims description 19
235000010355 mannitol Nutrition 0.000 claims description 19
FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 claims description 17
239000002702 enteric coating Substances 0.000 claims description 14
238000009505 enteric coating Methods 0.000 claims description 14
230000036470 plasma concentration Effects 0.000 claims description 13
238000009165 androgen replacement therapy Methods 0.000 claims description 6
239000003814 drug Substances 0.000 claims description 5
238000002360 preparation method Methods 0.000 claims description 5
206010002261 Androgen deficiency Diseases 0.000 claims description 4
206010016654 Fibrosis Diseases 0.000 claims description 4
208000018565 Hemochromatosis Diseases 0.000 claims description 4
201000007493 Kallmann syndrome Diseases 0.000 claims description 4
206010053142 Olfacto genital dysplasia Diseases 0.000 claims description 4
230000005856 abnormality Effects 0.000 claims description 4
238000002512 chemotherapy Methods 0.000 claims description 4
230000007882 cirrhosis Effects 0.000 claims description 4
208000019425 cirrhosis of liver Diseases 0.000 claims description 4
230000006378 damage Effects 0.000 claims description 4
230000002068 genetic effect Effects 0.000 claims description 4
239000001866 hydroxypropyl methyl cellulose Substances 0.000 claims description 4
229920003088 hydroxypropyl methyl cellulose Polymers 0.000 claims description 4
235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 claims description 4
UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 claims description 4
239000000463 material Substances 0.000 claims description 4
208000011580 syndromic disease Diseases 0.000 claims description 4
208000007848 Alcoholism Diseases 0.000 claims description 3
208000030453 Drug-Related Side Effects and Adverse reaction Diseases 0.000 claims description 3
208000008589 Obesity Diseases 0.000 claims description 3
208000027418 Wounds and injury Diseases 0.000 claims description 3
201000007930 alcohol dependence Diseases 0.000 claims description 3
208000020832 chronic kidney disease Diseases 0.000 claims description 3
208000022831 chronic renal failure syndrome Diseases 0.000 claims description 3
208000015181 infectious disease Diseases 0.000 claims description 3
208000027866 inflammatory disease Diseases 0.000 claims description 3
208000014674 injury Diseases 0.000 claims description 3
235000020824 obesity Nutrition 0.000 claims description 3
230000006584 pituitary dysfunction Effects 0.000 claims description 3
238000001959 radiotherapy Methods 0.000 claims description 3
230000035882 stress Effects 0.000 claims description 3
230000002381 testicular Effects 0.000 claims description 3
201000003585 eunuchism Diseases 0.000 claims description 2
208000037106 male hypogonadism Diseases 0.000 claims description 2
229920003145 methacrylic acid copolymer Polymers 0.000 claims description 2
229940117841 methacrylic acid copolymer Drugs 0.000 claims description 2
238000002203 pretreatment Methods 0.000 claims description 2
RFVFQQWKPSOBED-PSXMRANNSA-N 1-myristoyl-2-palmitoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)O[C@@H](COP([O-])(=O)OCC[N+](C)(C)C)COC(=O)CCCCCCCCCCCCC RFVFQQWKPSOBED-PSXMRANNSA-N 0.000 abstract description 22
GZDFHIJNHHMENY-UHFFFAOYSA-N Dimethyl dicarbonate Chemical compound COC(=O)OC(=O)OC GZDFHIJNHHMENY-UHFFFAOYSA-N 0.000 abstract description 17
150000003904 phospholipids Chemical class 0.000 abstract description 10
CITHEXJVPOWHKC-UUWRZZSWSA-N 1,2-di-O-myristoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCCCCCCC CITHEXJVPOWHKC-UUWRZZSWSA-N 0.000 abstract description 3
241000282472 Canis lupus familiaris Species 0.000 description 92
NVKAWKQGWWIWPM-ABEVXSGRSA-N 17-β-hydroxy-5-α-Androstan-3-one Chemical compound C1C(=O)CC[C@]2(C)[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CC[C@H]21 NVKAWKQGWWIWPM-ABEVXSGRSA-N 0.000 description 19
229960003473 androstanolone Drugs 0.000 description 17
230000037396 body weight Effects 0.000 description 15
AOQIVBOEDICQDB-KNWHVVHCSA-N [(5s,8r,9s,10s,13s,14s,17s)-10,13-dimethyl-3-oxo-1,2,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydrocyclopenta[a]phenanthren-17-yl] undecanoate Chemical compound C([C@@H]1CC2)C(=O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H](OC(=O)CCCCCCCCCC)[C@@]2(C)CC1 AOQIVBOEDICQDB-KNWHVVHCSA-N 0.000 description 13
239000002609 medium Substances 0.000 description 13
WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 12
NRJAVPSFFCBXDT-HUESYALOSA-N 1,2-distearoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCCCCCCCCCCC NRJAVPSFFCBXDT-HUESYALOSA-N 0.000 description 11
239000008280 blood Substances 0.000 description 10
210000004369 blood Anatomy 0.000 description 10
238000000034 method Methods 0.000 description 10
WRIDQFICGBMAFQ-UHFFFAOYSA-N (E)-8-Octadecenoic acid Natural products CCCCCCCCCC=CCCCCCCC(O)=O WRIDQFICGBMAFQ-UHFFFAOYSA-N 0.000 description 8
LQJBNNIYVWPHFW-UHFFFAOYSA-N 20:1omega9c fatty acid Natural products CCCCCCCCCCC=CCCCCCCCC(O)=O LQJBNNIYVWPHFW-UHFFFAOYSA-N 0.000 description 8
QSBYPNXLFMSGKH-UHFFFAOYSA-N 9-Heptadecensaeure Natural products CCCCCCCC=CCCCCCCCC(O)=O QSBYPNXLFMSGKH-UHFFFAOYSA-N 0.000 description 8
ZQPPMHVWECSIRJ-UHFFFAOYSA-N Oleic acid Natural products CCCCCCCCC=CCCCCCCCC(O)=O ZQPPMHVWECSIRJ-UHFFFAOYSA-N 0.000 description 8
239000005642 Oleic acid Substances 0.000 description 8
239000002552 dosage form Substances 0.000 description 8
QXJSBBXBKPUZAA-UHFFFAOYSA-N isooleic acid Natural products CCCCCCCC=CCCCCCCCCC(O)=O QXJSBBXBKPUZAA-UHFFFAOYSA-N 0.000 description 8
208000024891 symptom Diseases 0.000 description 8
241001465754 Metazoa Species 0.000 description 7
ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 description 7
150000002632 lipids Chemical class 0.000 description 6
206010058359 Hypogonadism Diseases 0.000 description 5
239000012530 fluid Substances 0.000 description 5
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 5
231100000673 dose–response relationship Toxicity 0.000 description 4
238000004128 high performance liquid chromatography Methods 0.000 description 4
230000000968 intestinal effect Effects 0.000 description 4
229910019142 PO4 Inorganic materials 0.000 description 3
HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
238000010521 absorption reaction Methods 0.000 description 3
239000007963 capsule composition Substances 0.000 description 3
229940079593 drug Drugs 0.000 description 3
235000013305 food Nutrition 0.000 description 3
238000000265 homogenisation Methods 0.000 description 3
239000004615 ingredient Substances 0.000 description 3
239000002245 particle Substances 0.000 description 3
239000010452 phosphate Substances 0.000 description 3
NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 3
229910052708 sodium Inorganic materials 0.000 description 3
239000011734 sodium Substances 0.000 description 3
238000012360 testing method Methods 0.000 description 3
208000017924 Klinefelter Syndrome Diseases 0.000 description 2
229920000168 Microcrystalline cellulose Polymers 0.000 description 2
229920002472 Starch Polymers 0.000 description 2
238000002835 absorbance Methods 0.000 description 2
230000032683 aging Effects 0.000 description 2
238000004458 analytical method Methods 0.000 description 2
230000015572 biosynthetic process Effects 0.000 description 2
239000008366 buffered solution Substances 0.000 description 2
239000011248 coating agent Substances 0.000 description 2
238000000576 coating method Methods 0.000 description 2
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
230000002496 gastric effect Effects 0.000 description 2
239000003365 glass fiber Substances 0.000 description 2
230000002267 hypothalamic effect Effects 0.000 description 2
238000001727 in vivo Methods 0.000 description 2
210000004347 intestinal mucosa Anatomy 0.000 description 2
235000019813 microcrystalline cellulose Nutrition 0.000 description 2
239000008108 microcrystalline cellulose Substances 0.000 description 2
229940016286 microcrystalline cellulose Drugs 0.000 description 2
210000000813 small intestine Anatomy 0.000 description 2
239000008107 starch Substances 0.000 description 2
235000019698 starch Nutrition 0.000 description 2
238000011282 treatment Methods 0.000 description 2
206010000029 5-alpha-reductase deficiency Diseases 0.000 description 1
208000030507 AIDS Diseases 0.000 description 1
206010056292 Androgen-Insensitivity Syndrome Diseases 0.000 description 1
239000004135 Bone phosphate Substances 0.000 description 1
206010007558 Cardiac failure chronic Diseases 0.000 description 1
206010011498 Cryptorchism Diseases 0.000 description 1
208000010228 Erectile Dysfunction Diseases 0.000 description 1
229920003134 Eudragit® polymer Polymers 0.000 description 1
108010010803 Gelatin Proteins 0.000 description 1
DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
CERQOIWHTDAKMF-UHFFFAOYSA-N Methacrylic acid Chemical compound CC(=C)C(O)=O CERQOIWHTDAKMF-UHFFFAOYSA-N 0.000 description 1
VVQNEPGJFQJSBK-UHFFFAOYSA-N Methyl methacrylate Chemical compound COC(=O)C(C)=C VVQNEPGJFQJSBK-UHFFFAOYSA-N 0.000 description 1
206010068871 Myotonic dystrophy Diseases 0.000 description 1
206010028980 Neoplasm Diseases 0.000 description 1
206010031068 Orchitis mumps Diseases 0.000 description 1
208000001132 Osteoporosis Diseases 0.000 description 1
208000014993 Pituitary disease Diseases 0.000 description 1
108700004960 Pseudovaginal Perineoscrotal Hypospadias Proteins 0.000 description 1
208000001647 Renal Insufficiency Diseases 0.000 description 1
206010059594 Secondary hypogonadism Diseases 0.000 description 1
DOOTYTYQINUNNV-UHFFFAOYSA-N Triethyl citrate Chemical compound CCOC(=O)CC(O)(C(=O)OCC)CC(=O)OCC DOOTYTYQINUNNV-UHFFFAOYSA-N 0.000 description 1
TVAOPZBTOBRXMP-KRAWVPEZSA-N [(2R)-2,3-di(hexadecanoyloxy)propyl] 2-(trimethylazaniumyl)ethyl phosphate [(2R)-2,3-di(octadecanoyloxy)propyl] 2-(trimethylazaniumyl)ethyl phosphate Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCCCCCCCCC.CCCCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCCCCCCCCCCC TVAOPZBTOBRXMP-KRAWVPEZSA-N 0.000 description 1
230000002378 acidificating effect Effects 0.000 description 1
238000000540 analysis of variance Methods 0.000 description 1
239000003098 androgen Substances 0.000 description 1
229940030486 androgens Drugs 0.000 description 1
229920006318 anionic polymer Polymers 0.000 description 1
230000000181 anti-adherent effect Effects 0.000 description 1
239000007864 aqueous solution Substances 0.000 description 1
238000004364 calculation method Methods 0.000 description 1
230000019771 cognition Effects 0.000 description 1
201000000160 cryptorchidism Diseases 0.000 description 1
230000007423 decrease Effects 0.000 description 1
230000003247 decreasing effect Effects 0.000 description 1
230000007547 defect Effects 0.000 description 1
230000007812 deficiency Effects 0.000 description 1
238000013461 design Methods 0.000 description 1
238000001514 detection method Methods 0.000 description 1
206010012601 diabetes mellitus Diseases 0.000 description 1
239000003085 diluting agent Substances 0.000 description 1
201000010099 disease Diseases 0.000 description 1
208000035475 disorder Diseases 0.000 description 1
238000004090 dissolution Methods 0.000 description 1
239000012738 dissolution medium Substances 0.000 description 1
230000000694 effects Effects 0.000 description 1
238000005516 engineering process Methods 0.000 description 1
230000007717 exclusion Effects 0.000 description 1
235000020937 fasting conditions Nutrition 0.000 description 1
125000000524 functional group Chemical group 0.000 description 1
229920000159 gelatin Polymers 0.000 description 1
239000008273 gelatin Substances 0.000 description 1
235000019322 gelatine Nutrition 0.000 description 1
235000011852 gelatine desserts Nutrition 0.000 description 1
238000007429 general method Methods 0.000 description 1
238000000227 grinding Methods 0.000 description 1
239000007902 hard capsule Substances 0.000 description 1
229940088597 hormone Drugs 0.000 description 1
239000005556 hormone Substances 0.000 description 1
150000004677 hydrates Chemical class 0.000 description 1
230000036571 hydration Effects 0.000 description 1
238000006703 hydration reaction Methods 0.000 description 1
201000003368 hypogonadotropic hypogonadism Diseases 0.000 description 1
201000002733 hypogonadotropic hypogonadism 23 with or without anosmia Diseases 0.000 description 1
201000001881 impotence Diseases 0.000 description 1
238000000338 in vitro Methods 0.000 description 1
238000002347 injection Methods 0.000 description 1
239000007924 injection Substances 0.000 description 1
201000006370 kidney failure Diseases 0.000 description 1
239000007788 liquid Substances 0.000 description 1
239000006194 liquid suspension Substances 0.000 description 1
230000001926 lymphatic effect Effects 0.000 description 1
210000004324 lymphatic system Anatomy 0.000 description 1
230000004060 metabolic process Effects 0.000 description 1
238000010606 normalization Methods 0.000 description 1
239000000546 pharmaceutical excipient Substances 0.000 description 1
239000008363 phosphate buffer Substances 0.000 description 1
230000001817 pituitary effect Effects 0.000 description 1
208000017402 pituitary gland disease Diseases 0.000 description 1
239000004014 plasticizer Substances 0.000 description 1
238000011160 research Methods 0.000 description 1
201000000306 sarcoidosis Diseases 0.000 description 1
238000000926 separation method Methods 0.000 description 1
230000036299 sexual function Effects 0.000 description 1
239000007901 soft capsule Substances 0.000 description 1
238000007921 solubility assay Methods 0.000 description 1
239000000243 solution Substances 0.000 description 1
210000002784 stomach Anatomy 0.000 description 1
239000000126 substance Substances 0.000 description 1
239000000725 suspension Substances 0.000 description 1
239000000454 talc Substances 0.000 description 1
229910052623 talc Inorganic materials 0.000 description 1
210000001550 testis Anatomy 0.000 description 1
239000001069 triethyl citrate Substances 0.000 description 1
VMYFZRTXGLUXMZ-UHFFFAOYSA-N triethyl citrate Natural products CCOC(=O)C(O)(C(=O)OCC)C(=O)OCC VMYFZRTXGLUXMZ-UHFFFAOYSA-N 0.000 description 1
235000013769 triethyl citrate Nutrition 0.000 description 1
ZDPHROOEEOARMN-UHFFFAOYSA-N undecanoic acid Chemical group CCCCCCCCCCC(O)=O ZDPHROOEEOARMN-UHFFFAOYSA-N 0.000 description 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
- A61K31/568—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/24—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
- A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
- A61K9/1277—Preparation processes; Proliposomes
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
- A61K9/145—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4891—Coated capsules; Multilayered drug free capsule shells
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/06—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
- A61P5/26—Androgens

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Animal Behavior & Ethology (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Epidemiology (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Organic Chemistry (AREA)
Endocrinology (AREA)
Dispersion Chemistry (AREA)
Diabetes (AREA)
Nutrition Science (AREA)
Physiology (AREA)
Oil, Petroleum & Natural Gas (AREA)
Molecular Biology (AREA)
Reproductive Health (AREA)
Biochemistry (AREA)
Biophysics (AREA)
Gynecology & Obstetrics (AREA)
Pregnancy & Childbirth (AREA)
Urology & Nephrology (AREA)
Gastroenterology & Hepatology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicinal Preparation (AREA)

TW109127792A 2019-08-09 2020-08-14 前體脂質體十一酸睪固酮調配物 TWI867026B (zh)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
US201962884919P	2019-08-09	2019-08-09
PCT/US2020/045607 WO2021030260A1 (fr)	2019-08-09	2020-08-10	Formulations d'undécanoate de testostérone proliposomales
WOPCT/US20/45607		2020-08-10

Publications (2)

Publication Number	Publication Date
TW202216162A TW202216162A (zh)	2022-05-01
TWI867026B true TWI867026B (zh)	2024-12-21

Family

ID=74569809

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
TW109127792A TWI867026B (zh)	2019-08-09	2020-08-14	前體脂質體十一酸睪固酮調配物

Country Status (13)

Country	Link
US (1)	US20220265679A1 (fr)
EP (1)	EP4009950A4 (fr)
JP (1)	JP2022544197A (fr)
KR (1)	KR20220054318A (fr)
CN (1)	CN114667133B (fr)
AR (1)	AR122300A1 (fr)
AU (1)	AU2020329775A1 (fr)
BR (1)	BR112022002418A2 (fr)
CA (1)	CA3146515A1 (fr)
IL (1)	IL290464A (fr)
MX (1)	MX2022001417A (fr)
TW (1)	TWI867026B (fr)
WO (1)	WO2021030260A1 (fr)

Citations (1)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US9844557B2 (en) *	2012-05-09	2017-12-19	Western University Of Health Sciences	Proliposomal testosterone formulations

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US8658202B2 (en) *	2001-04-25	2014-02-25	Western University Of Health Sciences	Coated drug delivery formulations
US6759058B1 (en) *	2001-04-25	2004-07-06	Western Center For Drug Development College Of Pharmacy Western University Of Health Sciences	Enteric-coated proliposomal formulations for poorly water soluble drugs
US20120135074A1 (en) *	2010-11-30	2012-05-31	Chandrashekar Giliyar	High-Strength Testosterone Undecanoate Compositions
CN105188675A (zh) *	2013-03-13	2015-12-23	马林克罗特有限公司	经修饰多西他赛脂质体制剂
WO2017120586A1 (fr) *	2016-01-07	2017-07-13	Western University Of Health Sciences	Formulations pour le traitement du cancer de la vessie
EP3399965A4 (fr) *	2016-01-08	2019-08-21	Western University Of Health Sciences	Formulations d'undécanoate de testostérone proliposomales
EP3538074B1 (fr) *	2016-11-11	2023-07-26	Western University Of Health Sciences	Méthodes de traitement de carcinomes urothéliaux de la voie excrétrice supérieure

2020
- 2020-08-10 US US17/631,525 patent/US20220265679A1/en active Pending
- 2020-08-10 BR BR112022002418A patent/BR112022002418A2/pt unknown
- 2020-08-10 CN CN202080068370.2A patent/CN114667133B/zh active Active
- 2020-08-10 CA CA3146515A patent/CA3146515A1/fr active Pending
- 2020-08-10 EP EP20853110.3A patent/EP4009950A4/fr active Pending
- 2020-08-10 JP JP2022507828A patent/JP2022544197A/ja active Pending
- 2020-08-10 AR ARP200102272A patent/AR122300A1/es unknown
- 2020-08-10 MX MX2022001417A patent/MX2022001417A/es unknown
- 2020-08-10 KR KR1020227007814A patent/KR20220054318A/ko not_active Ceased
- 2020-08-10 AU AU2020329775A patent/AU2020329775A1/en not_active Abandoned
- 2020-08-10 WO PCT/US2020/045607 patent/WO2021030260A1/fr not_active Ceased
- 2020-08-14 TW TW109127792A patent/TWI867026B/zh active
2022
- 2022-02-08 IL IL290464A patent/IL290464A/en unknown

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US9844557B2 (en) *	2012-05-09	2017-12-19	Western University Of Health Sciences	Proliposomal testosterone formulations

Also Published As

Publication number	Publication date
AU2020329775A1 (en)	2022-02-24
JP2022544197A (ja)	2022-10-17
TW202216162A (zh)	2022-05-01
EP4009950A4 (fr)	2023-07-05
IL290464A (en)	2022-04-01
AR122300A1 (es)	2022-08-31
BR112022002418A2 (pt)	2022-06-14
KR20220054318A (ko)	2022-05-02
CA3146515A1 (fr)	2021-02-18
MX2022001417A (es)	2022-06-08
CN114667133B (zh)	2025-01-14
CN114667133A (zh)	2022-06-24
WO2021030260A1 (fr)	2021-02-18
US20220265679A1 (en)	2022-08-25
EP4009950A1 (fr)	2022-06-15

Publication	Publication Date	Title
JP5433236B2 (ja)	2014-03-05	弱塩基性選択性セロトニン５−ｈｔ３遮断剤および有機酸を含む薬物送達系
KR101489401B1 (ko)	2015-02-03	약 염기성 약물과 유기산을 포함하는 약물 전달 시스템
JP3725539B2 (ja)	2005-12-14	ビサコジル剤形
US20020132001A1 (en)	2002-09-19	Aldosterone antagonist composition for release during aldosterone acrophase
US20190248830A1 (en)	2019-08-15	Proliposomal testosterone undecanoate formulations
CZ293616B6 (cs)	2004-06-16	Léčivo a farmaceutická kompozice pro dodávku nikotinu a komplex nikotinu a karbomeru a způsob jeho přípravy
KR20080072760A (ko)	2008-08-06	ｇａｎａｘｏｌｏｎｅ 제형, 이의 제조방법 및 용도
MX2008016115A (es)	2009-01-20	Composiciones que comprenden meloxicam nanoparticulado e hidrocodona de liberacion controlada.
US20130004563A1 (en)	2013-01-03	Multiparticulate s-adenosylmethionine compositions and related methods
CN108348475A (zh)	2018-07-31	处于液体剂型的多层药学活性化合物释放微粒
KR102300335B1 (ko)	2021-09-10	아프레피탄트의 경구용 조성물
BR112021003788A2 (pt)	2021-06-08	formas de dosagem pediátrica, métodos de fabricação e uso de vitamina d
JP2009543803A (ja)	2009-12-10	モダフィニルのナノ粒子製剤
US20240358650A1 (en)	2024-10-31	Inhalable hormone receptor agonist formulations
CN107530337A (zh)	2018-01-02	治疗方法
TWI867026B (zh)	2024-12-21	前體脂質體十一酸睪固酮調配物
CN101287453A (zh)	2008-10-15	包含头孢菌素的毫微粒和控制释放组合物
CN114340615A (zh)	2022-04-12	用于施用治疗剂的制品和方法
EP4505999A1 (fr)	2025-02-12	Formulations de probénécides
HK1259799A1 (en)	2019-12-06	Proliposomal testosterone undecanoate formulations
HK1230944B (zh)	2019-10-18	包衣藥物球狀體及其製備消除或減少病症的藥物的用途